The NEK family of serine/threonine kinases as a biomarker for cancer.
Breast cancer
Cell cycle
Lung cancer
NEK kinases
Ovarian cancer
Pancreatic cancer
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
04
10
2021
accepted:
01
12
2021
pubmed:
18
1
2022
medline:
25
2
2023
entrez:
17
1
2022
Statut:
ppublish
Résumé
Cancer is defined by unrestrained cell proliferation due to impaired protein activity. Cell cycle-related proteins are likely to play a role in human cancers, including proliferation, invasion, and therapeutic resistance. The serine/threonine NEK kinases are the part of Never In Mitosis A Kinases (NIMA) family, which are less explored kinase family involved in the cell cycle, checkpoint regulation, and cilia biology. They comprise of eleven members, namely NEK1, NEK2, NEK3, NEK4, NEK5, NEK6, NEK7, NEK8, NEK9, NEK10, and NEK11, located in different cellular regions. Recent research has shown the role of NEK family in various cancers by perversely expressing. Therefore, this review aimed to provide a systematic account of our understanding of NEK kinases; structural details; and its role in the cell cycle regulation. Furthermore, we have comprehensively reviewed the NEK kinases in terms of their expression and regulation in different cancers. Lastly, we have emphasized on some of the potential NEK inhibitors reported so far.
Identifiants
pubmed: 35037094
doi: 10.1007/s10238-021-00782-0
pii: 10.1007/s10238-021-00782-0
doi:
Substances chimiques
Protein Serine-Threonine Kinases
EC 2.7.11.1
NIMA-Related Kinases
EC 2.7.11.1
Cell Cycle Proteins
0
Biomarkers
0
Serine
452VLY9402
Threonine
2ZD004190S
NEK6 protein, human
EC 2.7.11.1
NEK9 protein, human
EC 2.7.11.1
NEK3 protein, human
EC 2.7.11.1
NEK2 protein, human
EC 2.7.11.1
Nek5 protein, human
EC 2.7.11.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-30Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ardito F, Giuliani M, Perrone D, Troiano G, Muzio LL. The crucial role of protein phosphorylation in cell signalingand its use as targeted therapy (Review). Int J Mol Med. 2017;40:271–80.
pubmed: 28656226
pmcid: 5500920
doi: 10.3892/ijmm.2017.3036
Bhullar KS, Lagarón NO, McGowan EM, Parmar I, Jha A, Hubbard BP, et al. Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer Mol Cancer. 2018;17:1–20.
Cicenas J, Zalyte E, Bairoch A, Gaudet P. Kinases and cancer. Cancers (Basel). 2018;10:1–7.
doi: 10.3390/cancers10010001
Clutterbuck AJ. Aspergillus nidulans. Bact Bacteriophages Fungi. 1974;96:447–510.
doi: 10.1007/978-1-4899-1710-2_26
Oakley BR, Morris NR. A mutation in Aspergillus nidulans that blocks the transition from interphase to prophase. J Cell Biol. 1983;96:1155–8.
pubmed: 6339527
pmcid: 2112314
doi: 10.1083/jcb.96.4.1155
Wu L, Osmani SA, Mirabito PM. A role for NIMA in the nuclear localization of cyclin B in Aspergillus nidulans. J Cell Biol. 1998;141:1575–87.
pubmed: 9647650
pmcid: 2133011
doi: 10.1083/jcb.141.7.1575
Moniz L, Dutt P, Haider N, Stambolic V. Nek family of kinases in cell cycle, checkpoint control and cancer. Cell Div [Internet]. BioMed Central Ltd; 2011;6:18. Available from: http://www.celldiv.com/content/6/1/18
Pavan ICB, Peres de Oliveira A, Dias PRF, Basei FL, Issayama LK, de Ferezin C, et al. On Broken Ne(c)ks and Broken DNA: the role of human NEKs in the DNA damage response. Cells. 2021;10:1–25.
doi: 10.3390/cells10030507
Kokuryo T, Yokoyama Y, Yamaguchi J, Tsunoda N, Ebata T, Nagino M. NEK2 is an effective target for cancer therapy with potential to induce regression of multiple human malignancies. Anticancer Res. 2019;39:2251–8.
pubmed: 31092416
doi: 10.21873/anticanres.13341
Johnson LN, Noble MEM, Owen DJ. Active and inactive protein kinases: structural basis for regulation. Cell. 1996;85:149–58.
pubmed: 8612268
doi: 10.1016/S0092-8674(00)81092-2
Belham C, Roig J, Caldwell JA, Aoyama Y, Kemp BE, Comb M, et al. A mitotic cascade of NIMA family kinases: Nercc1/Nek9 activates the Nek6 and Nek7 kinases. J Biol Chem [Internet]. © 2003 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.; 2003;278:34897–909. https://doi.org/10.1074/jbc.M303663200
Bertran MT, Sdelci S, Regué L, Avruch J, Caelles C, Roig J. Nek9 is a Plk1-activated kinase that controls early centrosome separation through Nek6/7 and Eg5. EMBO J. 2011;30:2634–47.
pubmed: 21642957
pmcid: 3155310
doi: 10.1038/emboj.2011.179
Kun Ping Lu, Kemp BE, Means AR. Identification of substrate specificity determinants for the cell cycle- regulated NIMA protein kinase. J Biol Chem. 1994;269:6603–7.
doi: 10.1016/S0021-9258(17)37415-X
Lizcano JM, Deak M, Morrice N, Kieloch A, James Hastie C, Dong L, et al. Molecular basis for the substrate specificity of NIMA-related kinase-6 (NEK6). Evidence that NEK6 does not phosphorylate the hydrophobic motif of ribosomal S6 protein kinase and serum- and glucocorticoid-induced protein kinase in vivo. J Biol Chem [Internet]. © 2002 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.; 2002;277:27839–49. https://doi.org/10.1074/jbc.M202042200
Alexander J, Lim D, Joughin BA, Hegemann B, Hutchins JR, Ehrenberger T, Ivins F, Sessa F, Hudecz O, Nigg EA, Fry AM, Musacchio A, Stukenberg PT, Mechtler K, Peters JM, Smerdon SJ, Yaffe MB. Spatial exclusivity combined with positive and negative selection of phosphorylation motifs is the basis for context-dependent mitotic signaling. Sci Signal. 2011;4(179):ra42. https://doi.org/10.1126/scisignal.2001796 .
doi: 10.1126/scisignal.2001796
pubmed: 21712545
pmcid: 3939359
Zalli D, Bayliss R, Fry AM. The Nek8 protein kinase, mutated in the human cystic kidney disease nephronophthisis, is both activated and degraded during ciliogenesis. Hum Mol Genet. 2012;21:1155–71.
pubmed: 22106379
doi: 10.1093/hmg/ddr544
Fry AM, O'Regan L, Sabir SR, Bayliss R. Cell cycle regulation by the NEK family of protein kinases. J Cell Sci. 2012;125(Pt 19):4423–33. https://doi.org/10.1242/jcs.111195 .
doi: 10.1242/jcs.111195
pubmed: 23132929
pmcid: 3500863
Pu RT, Osmani SA. Mitotic destruction of the cell cycle regulated NIMA protein kinase of Aspergillus nidulans is required for mitotic exit. EMBO J. 1995;14:995–1003.
pubmed: 7889945
pmcid: 398171
doi: 10.1002/j.1460-2075.1995.tb07080.x
Sedgwick GG, Hayward DG, Di Fiore B, Pardo M, Yu L, Pines J, et al. Mechanisms controlling the temporal degradation of Nek2A and Kif18A by the APC/C-Cdc20 complex. EMBO J. 2013;32:303–14.
pubmed: 23288039
pmcid: 3553385
doi: 10.1038/emboj.2012.335
Vaz Meirelles G, Ferreira Lanza DC, da Silva JC, Santana Bernachi J, Paes Leme AF, Kobarg J. Characterization of hNek6 interactome reveals an important role for its short N-terminal domain and colocalization with proteins at the centrosome. J Proteome Res United States. 2010;9:6298–316.
doi: 10.1021/pr100562w
Fry AM, Schultz SJ, Bartek J, Nigg EA. Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of Aspergillus nidulans. J Biol Chem [Internet]. © 1995 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.; 1995;270:12899–905. https://doi.org/10.1074/jbc.270.21.12899
Hardy T, Lee M, Hames RS, Prosser SL, Cheary D-M, Samant MD, et al. Multisite phosphorylation of C-Nap1 releases it from Cep135 to trigger centrosome disjunction. J Cell Sci [Internet]. 2014/04/02. The Company of Biologists; 2014;127:2493–506. https://pubmed.ncbi.nlm.nih.gov/24695856
Bahmanyar S, Kaplan DD, DeLuca JG, Giddings TH, O’Toole ET, Winey M, et al. β-catenin is a Nek2 substrate involved in centrosome separation. Genes Dev. 2008;22:91–105.
pubmed: 18086858
pmcid: 2151018
doi: 10.1101/gad.1596308
O’Regan L, Fry AM. The Nek6 and Nek7 protein kinases are required for robust mitotic spindle formation and cytokinesis. Mol Cell Biol. 2009;29:3975–90.
pubmed: 19414596
pmcid: 2704745
doi: 10.1128/MCB.01867-08
Sdelci S, Bertran MT, Roig J. Nek9, Nek6, Nek7 and the separation of centrosomes. Cell Cycle. 2011;10:3816–7. https://doi.org/10.4161/cc.10.22.18226 .
doi: 10.4161/cc.10.22.18226
pubmed: 22064517
Roig J, Mikhailov A, Belham C, Avruch J. Nercc1, a mammalian NIMA-family kinase, binds the Ran GTPase and regulates mitotic progression. Genes Dev. 2002;16:1640–58.
pubmed: 12101123
pmcid: 186374
doi: 10.1101/gad.972202
Rapley J, Nicolàs M, Groen A, Regué L, Bertran MT, Caelles C, Avruch J, Roig J. The NIMA-family kinase Nek6 phosphorylates the kinesin Eg5 at a novel site necessary for mitotic spindle formation. J Cell Sci. 2008;121(Pt 23):3912–21. https://doi.org/10.1242/jcs.035360 .
doi: 10.1242/jcs.035360
pubmed: 19001501
Kim S, Lee K, Rhee K. NEK7 is a centrosomal kinase critical for microtubule nucleation. Biochem Biophys Res Commun. 2007;360:56–62.
pubmed: 17586473
doi: 10.1016/j.bbrc.2007.05.206
Goshima G, Kimura A. New look inside the spindle: microtubule-dependent microtubule generation within the spindle. Curr Opin Cell Biol. 2010;22:44–9. https://doi.org/10.1016/j.ceb.2009.11.012 .
doi: 10.1016/j.ceb.2009.11.012
pubmed: 20022736
Slangy A, Lane HA, d’Hérin P, Harper M, Kress M, Niggt EA. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell. 1995;83:1159–69.
doi: 10.1016/0092-8674(95)90142-6
Gao Y, Cao D, Pawnikar S, John KP, Ahn HM, Hill S, Ha JM, Parikh P, Ogilvie C, Swain A, Yang A, Bell A, Salazar A, Miao Y, Liang B. Structure of the Human Respiratory Syncytial Virus M2–1 Protein in Complex with a Short Positive-Sense Gene-End RNA. Structure. 2020;28(9):979–990.e4. https://doi.org/10.1016/j.str.2020.07.001 .
doi: 10.1016/j.str.2020.07.001
pubmed: 32697936
pmcid: 7484405
Helfand BT, Mendez MG, Pugh J, Delsert C, Goldman RD. Maintaining the shape of nerve cells. Mol Biol Cell. 2003;14:5069–81.
pubmed: 14595112
pmcid: 284808
doi: 10.1091/mbc.e03-06-0376
Laurell E, Beck K, Krupina K, Theerthagiri G, Bodenmiller B, Horvath P, et al. Phosphorylation of Nup98 by multiple kinases is crucial for NPC disassembly during mitotic entry. Cell [Internet]. Elsevier Inc.; 2011;144:539–50. https://doi.org/10.1016/j.cell.2011.01.012
Holland PM, Milne A, Garka K, Johnson RS, Willis C, Sims JE, et al. Purification, cloning, and characterization of Nek8, a novel nima-related kinase, and its candidate substrate Bicd2. J Biol Chem [Internet]. © 2002 ASBMB. Currently published by Elsevier Inc; originally published by American Society for Biochemistry and Molecular Biology.; 2002;277:16229–40. https://doi.org/10.1074/jbc.M108662200
Wei R, Ngo B, Wu G, Lee WH. Phosphorylation of the Ndc80 complex protein, HEC1, by Nek2 kinase modulates chromosome alignment and signaling of the spindle assembly checkpoint. Mol Biol Cell. 2011;22:3584–94.
pubmed: 21832156
pmcid: 3183014
doi: 10.1091/mbc.e11-01-0012
Zhang B, Zhang H, Wang D, Han S, Wang K, Yao A, et al. Never in mitosis gene A-related kinase 6 promotes cell proliferation of hepatocellular carcinoma via cyclin B modulation. Oncol Lett. 2014;8:1163–8.
pubmed: 25120679
pmcid: 4114597
doi: 10.3892/ol.2014.2300
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Hayward DG, Clarke RB, Faragher AJ, Pillai MR, Hagan IM, Fry AM. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res. 2004;64:7370–6.
pubmed: 15492258
doi: 10.1158/0008-5472.CAN-04-0960
Marina M, Saavedra HI. Nek2 and Plk4: Prognostic markers, drivers of breast tumorigenesis and drug resistance. Front Biosci Landmark. 2014;19:352–65.
doi: 10.2741/4212
Harrison Pitner MK, Saavedra HI. Cdk4 and Nek2 signal Binucleation and centrosome amplification in a Her2+ breast cancer model. PLoS ONE. 2013;8:32–5.
doi: 10.1371/journal.pone.0065971
Lee J, Gollahon L. Mitotic perturbations induced by Nek2 overexpression require interaction with TRF1 in breast cancer cells. Cell Cycle. 2013;12:3599–614.
pubmed: 24091727
pmcid: 3903712
doi: 10.4161/cc.26589
Cappello P, Blaser H, Gorrini C, Lin DCC, Elia AJ, Wakeham A, et al. Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells. Oncogene Nat Publ Group. 2014;33:2375–84.
Nuncia-Cantarero M, Martinez-Canales S, Andrés-Pretel F, Santpere G, Ocaña A, Galan-Moya EM. Functional transcriptomic annotation and protein–protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer. Breast Cancer Res Treat [Internet]. Springer US; 2018;168:613–23. https://doi.org/10.1007/s10549-017-4652-3
Miller SL, DeMaria JE, Freier DO, Riegel AM, Clevenger CV. Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor. Mol Endocrinol. 2005;19:939–49.
pubmed: 15618286
doi: 10.1210/me.2004-0443
Pei J, Zhang J, Yang X, Wu Z, Sun C, Wang Z, et al. NEK5 promotes breast cancer cell proliferation through up-regulation of Cyclin A2. Mol Carcinog U S. 2019;58:933–43.
doi: 10.1002/mc.22982
Raj CTD, Kumar D, Chandra R, Reddy S, Raju D, James RA. COVID—19: molecular pathophysiology, genetic evolution and prospective therapeutics—a review. Arch Microbiol. 2021. https://doi.org/10.1007/s00203-021-02183-z .
doi: 10.1007/s00203-021-02183-z
pubmed: 34244831
pmcid: 7868660
Eisa NH, Jilani Y, Kainth K, Redd P, Lu S, Bougrine O, et al. The co-chaperone UNC45A is essential for the expression of mitotic kinase NEK7 and tumorigenesis. J Biol Chem. 2019;294:5246–60.
pubmed: 30737284
pmcid: 6462532
doi: 10.1074/jbc.RA118.006597
Milne RL, Burwinkel B, Michailidou K, Arias Perez JI, Pilar Zamora M, Menéndez-Rodríguez P, et al. Common non-synonymous SNPs associated with breast cancer susceptibility: Findings from the Breast Cancer Association Consortium. Hum Mol Genet. 2014;23:6096–111.
pubmed: 24943594
pmcid: 4204770
doi: 10.1093/hmg/ddu311
Lai XB, Nie YQ, Huang HL, Li YF, Cao CY, Yang H, et al. NIMA-related kinase 2 regulates hepatocellular carcinoma cell growth and proliferation. Oncol Lett. 2017;13:1587–94.
pubmed: 28454295
pmcid: 5403431
doi: 10.3892/ol.2017.5618
Lin S, Zhou S, Jiang S, Liu X, Wang Y, Zheng X, et al. NEK2 regulates stem-like properties and predicts poor prognosis in hepatocellular carcinoma. Oncol Rep. 2016;36:853–62.
pubmed: 27349376
doi: 10.3892/or.2016.4896
Wen S, Liu Y, Yang M, Yang K, Huang J, Feng D. Increased NEK2 in hepatocellular carcinoma promotes cancer progression and drug resistance by promoting PP1/Akt and Wnt activation. Oncol Rep. 2016;36:2193–9.
pubmed: 27509921
doi: 10.3892/or.2016.5009
Li G, Zhong Y, Shen Q, Zhou Y, Deng X, Li C, et al. NEK2 serves as a prognostic biomarker for hepatocellular carcinoma. Int J Oncol. 2017;50:405–13.
pubmed: 28101574
pmcid: 5238800
doi: 10.3892/ijo.2017.3837
Zhang Y, Wang W, Wang Y, Huang X, Zhang Z, Chen B, et al. NEK2 promotes hepatocellular carcinoma migration and invasion through modulation of the epithelial-mesenchymal transition. Oncol Rep. 2018;39:1023–33.
pubmed: 29399700
pmcid: 5802024
Zhou L, Wang Z, Xu X, Wan Y, Qu K, Fan H, et al. Nek7 is overexpressed in hepatocellular carcinoma and promotes hepatocellular carcinoma cell proliferation in vitro and in vivo. Oncotarget. 2016;7:18620–30.
pubmed: 26921196
pmcid: 4951314
doi: 10.18632/oncotarget.7620
Lu L, Zhai X, Yuan R. Clinical significance and prognostic value of Nek2 protein expression in colon cancer. Int J Clin Exp Pathol. 2015;8:15467–73.
pubmed: 26823916
pmcid: 4713702
Kasap E, Gerceker E, Boyacıoglu SÖ, Yuceyar H, Yıldırm H, Ayhan S, et al. The potential role of the NEK6, AURKA, AURKB, and PAK1 genes in adenomatous colorectal polyps and colorectal adenocarcinoma. Tumor Biol. 2016;37:3071–80. https://doi.org/10.1007/s13277-015-4131-6 .
doi: 10.1007/s13277-015-4131-6
Gerçeker E, Boyacioglu SO, Kasap E, Baykan A, Yuceyar H, Yildirim H, et al. Never in mitosis gene A-related kinase 6 and aurora kinase A: new gene biomarkers in the conversion from ulcerative colitis to colorectal cancer. Oncol Rep. 2015;34:1905–14.
pubmed: 26259750
doi: 10.3892/or.2015.4187
Sabir SR, Sahota NK, Jones GDD, Fry AM. Loss of Nek11 prevents G2/M arrest and promotes cell death in HCT116 colorectal cancer cells exposed to therapeutic DNA damaging agents. PLoS ONE. 2015;10:1–19.
doi: 10.1371/journal.pone.0140975
Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. The TLK1-Nek1 axis promotes prostate cancer progression. Cancer Lett. 2019;453:131–41. https://doi.org/10.1016/j.canlet.2019.03.041 .
doi: 10.1016/j.canlet.2019.03.041
pubmed: 30928383
Singh V, Jaiswal PK, Ghosh I, Koul HK, Yu X, De Benedetti A. Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors. Int J Cancer. 2019;145:1055–67.
pubmed: 30737777
pmcid: 6617729
doi: 10.1002/ijc.32200
Atish DC, Anna CS, Maura BC, Rosina TL, Katherine L, Ying JL, et al. Castration resistance in prostate cancer is mediated by the kinase NEK6. Cancer Res. 2017;77:753–65.
doi: 10.1158/0008-5472.CAN-16-0455
Shi Y-X, Yin J-Y, Shen Y, Zhang W, Zhou H-H, Liu Z-Q. Genome-scale analysis identifies NEK2, DLGAP5 and ECT2 as promising diagnostic and prognostic biomarkers in human lung cancer. Sci Rep. 2017;7:8072. https://doi.org/10.1038/s41598-017-08615-5 .
doi: 10.1038/s41598-017-08615-5
pubmed: 28808310
pmcid: 5556079
The American Cancer Society medical and editorial content team. Colorectal Cancer Stages. Am Cancer Soc Med Inf [Internet]. 2017;1–11. Available from: https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/staged.html#references
Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Upregulation of NEK2 is associated with drug resistance in ovarian cancer. Oncol Rep Greece. 2014;31:745–54.
doi: 10.3892/or.2013.2910
De Donato M, Fanelli M, Mariani M, Raspaglio G, Pandya D, He S, et al. Nek6 and Hif-1α cooperate with the cytoskeletal gateway of drug resistance to drive outcome in serous ovarian cancer. Am J Cancer Res. 2015;5:1862–77.
pubmed: 26269749
pmcid: 4529609
Liu X, Gao Y, Lu Y, Zhang J, Li L, Yin F. Downregulation of NEK11 is associated with drug resistance in ovarian cancer. Int J Oncol. 2014;45:1266–74.
pubmed: 24969318
doi: 10.3892/ijo.2014.2503
Kokuryo T, Hibino S, Suzuki K, Watanabe K, Yokoyama Y, Nagino M, et al. Nek2 siRNA therapy using a portal venous port–catheter system for liver metastasis in pancreatic cancer. Cancer Sci. 2016;107:1315–20.
pubmed: 27316377
pmcid: 5021025
doi: 10.1111/cas.12993
Yan Z, Qu J, Li Z, Yi J, Su Y, Lin Q, et al. NEK7 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Front Oncol. 2021;11:1–13.
doi: 10.3389/fonc.2021.705797
Chen F, Feng Z, Zhu J, Liu P, Yang C, Huang R, et al. Emerging roles of circRNA_NEK6 targeting miR-370–3p in the proliferation and invasion of thyroid cancer via Wnt signaling pathway. Cancer Biol Ther. 2018;19:1139–52. https://doi.org/10.1080/15384047.2018.1480888 .
doi: 10.1080/15384047.2018.1480888
pubmed: 30207869
pmcid: 6301817
Cao Y, Song J, Chen J, Xiao J, Ni J, Wu C. Overexpression of NEK3 is associated with poor prognosis in patients with gastric cancer. Med (U S). 2018;97:1–5.
Orenay-Boyacioglu S, Kasap E, Gerceker E, Yuceyar H, Demirci U, Bilgic F, et al. Expression profiles of histone modification genes in gastric cancer progression. Mol Biol Rep. 2018;45:2275–82. https://doi.org/10.1007/s11033-018-4389-z .
doi: 10.1007/s11033-018-4389-z
pubmed: 30250993
Xu J, He Q, He X, Shao Q, Tao H, Ye Z. Expression of NEK-6 in gastric cancer and its clinical significance. Zhonghua Wei Chang Wai Ke Za Zhi China. 2015;18:1036–40.
Takeno A, Takemasa I, Doki Y, Yamasaki M, Miyata H, Takiguchi S, et al. Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br J Cancer. 2008;99:1307–15.
pubmed: 18827816
pmcid: 2570518
doi: 10.1038/sj.bjc.6604682
Ding XF, Chen J, Zhou J, Chen G, Wu YL. Never-in-mitosis a-related kinase 8, a novel targof von-hippel-lindau tumor suppressor protein, promotes gastric cancer cell proliferation. Oncol Lett. 2018;16:5900–6.
pubmed: 30333866
pmcid: 6176424
Connell NT, Berliner N. Fostamatinib for the treatment of chronic immune thrombocytopenia. Blood. 2019;133:2027–30.
pubmed: 30803989
doi: 10.1182/blood-2018-11-852491
Zhang Z, Fang C, Wang Y, Zhang J, Yu J, Zhang Y, et al. COL1A1: a potential therapeutic target for colorectal cancer expressing wild-Type or mutant KRAS. Int J Oncol. 2018;53:1869–80.
pubmed: 30132520
pmcid: 6192778
Rheault TR, Stellwagen JC, Adjabeng GM, Hornberger KR, Petrov KG, Waterson AG, et al. Discovery of dabrafenib: a selective inhibitor of Raf Kinases with antitumor activity against B-Raf-driven tumors. ACS Med Chem Lett. 2013;4:358–62.
pubmed: 24900673
pmcid: 4027516
doi: 10.1021/ml4000063
Zhou X, Zhang P, Wang Q, Ji N, Xia S, Ding Y, et al. Metformin ameliorates experimental diabetic periodontitis independently of mammalian target of rapamycin (mTOR) inhibition by reducing NIMA-related kinase 7(Nek7) expression. J Periodontol U S. 2019;90:1032–42.
doi: 10.1002/JPER.18-0528
De Donato M, Righino B, Filippetti F, Battaglia A, Petrillo M, Pirolli D, et al. Identification and antitumor activity of a novel inhibitor of the NIMA-related kinase NEK6. Sci Rep. 2018;8:1–13. https://doi.org/10.1038/s41598-018-34471-y .
doi: 10.1038/s41598-018-34471-y
Perera AP, Fernando R, Shinde T, Gundamaraju R, Southam B, Sohal SS, et al. MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice. Sci Rep. 2018;8:1–15. https://doi.org/10.1038/s41598-018-26775-w .
doi: 10.1038/s41598-018-26775-w
Xi J-B, Fang Y-F, Frett B, Zhu M-L, Zhu T, Kong Y-N, et al. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem France. 2017;126:1083–106.
doi: 10.1016/j.ejmech.2016.12.026